Exactly. Hampel was on the a SAB when that took place and hes publishing the data that he help develop at the time.
19 of 21 patients got worse. All patients with MMSE scores below 20 got worst. Its a house of cards. Don't even get me started on survivor bias.
What baffles me is if one looks at that data around 48 weeks (length of current trial for comparison) and would think that any type of provisional approval is imminent. Between the double blinding and the placebo group and the fact that so many patients track SOC or worse, I just don't see how that conclusion could be reached. Current trial does not take any of the papers "biomarker" conclusions or genetic disposition into consideration either. No reason to expect the results to be much different at all. JMHO
Market Data 
Markets 
AI
